Doxazosin
دوکسازوسین
❤️ Cardiovascular SystemAlpha-1 blocker
Market / country: 🇺🇸 USA
Cardura (US)
🧮 Dose calculator
Benign prostatic hyperplasia (BPH) · Regimen source: FDA Doxazosin · 2.2
- • Postural hypotension and syncope with the first dose or dose increases; monitor BP for up to 6 h. FDA Doxazosin · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to quinazolines (prazosin, terazosin, doxazosin). FDA Doxazosin · 4
Important interactions
- • PDE5 inhibitors: symptomatic hypotension. FDA Doxazosin · 5
Formulations
- 1 mg tablet (scored) — tablet 🇺🇸 USA FDA Doxazosin · 3
- 2 mg tablet (scored) — tablet 🇺🇸 USA FDA Doxazosin · 3
- 4 mg tablet (scored) — tablet 🇺🇸 USA FDA Doxazosin · 3
- 8 mg tablet (scored) — tablet 🇺🇸 USA FDA Doxazosin · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Doxazosin · 8.1
“Risk Summary The limited available data with doxazosin tablets in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Doxazosin · 8.2
“Risk Summary There is limited information on the presence of doxazosin in human milk [ see Data ].”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Doxazosin · 8.4
“The safety and effectiveness of doxazosin tablets have not been established in children.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Doxazosin · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA075580
- DailyMed (FDA label)FDA Doxazosin
- MedlinePlus (NIH)Doxazosin
- WHO ATC/DDDC02CA04
- Darooyab (Iran)Doxazosin
🇮🇷 Registered in Iran Darooyab · G-1654/Doxazosin
Dosage forms with Iranian generic codes, per Darooyab.
- 11246 · DOXAZOSIN 1MG TAB · قرص دوکسازوسین ۱ میلیگرم
- 06773 · DOXAZOSIN 2MG TAB · قرص دوکسازوسین ۲ میلیگرم
- 20964 · DOXAZOSIN 4MG CAP · کپسول دوکسازوسین ۴ میلیگرم
- 05059 · DOXAZOSIN 4MG TAB · قرص دوکسازوسین ۴ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Doxazosin · 3FDA Doxazosin · 2.2FDA Doxazosin · 2.1FDA Doxazosin · 2.3FDA Doxazosin · 4FDA Doxazosin · 5FDA Doxazosin · 8.1FDA Doxazosin · 8.2FDA Doxazosin · 8.4FDA Doxazosin · 8.5FDA Doxazosin · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1654/Doxazosin
- Clinical review⚠ Unverified